In particular the BCL2-specific BH3-mimetic venetoclax (ABT-199) has shown high activity ex vivo and in vivo in a subset of B-cell precursor ALL (Fischer et al., 2015) and in some T-cell leukemia samples (Chonghaile et al., 2014; Peirs et al., 2014; Frismantas et al., 2017). This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.